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C-terminal binding protein 1 (CtBP1) and CtBP2 are tran-
scriptional coregulators that repress numerous cellular pro-
cesses, such as apoptosis, by binding transcription factors and
recruiting chromatin-remodeling enzymes to gene promoters.
The NAD(H)-linked oligomerization of human CtBP is coupled
to its co-transcriptional activity, which is implicated in cancer
progression. However, the biologically relevant level of CtBP
assembly has not been firmly established; nor has the stereo-
chemical arrangement of the subunits above that of a dimer.
Here, multi-angle light scattering (MALS) data established the
NAD- and NADH-dependent assembly of CtBP1 and CtBP2
into tetramers. An examination of subunit interactions within
CtBP1 and CtBP2 crystal lattices revealed that both share a very
similar tetrameric arrangement resulting from assembly of two
dimeric pairs,with specific interactionsprobably being sensitive
to NAD(H) binding. Creating a series of mutants of both CtBP1
andCtBP2, we tested the hypothesis that the crystallographically
observed interdimer pairing stabilizes the solution tetramer.
MALS data confirmed that these mutants disrupt both CtBP1
and CtBP2 tetramers, with the dimer generally remaining
intact, providing the first stereochemical models for tetrameric
assemblies ofCtBP1 andCtBP2. The crystal structure of a subtle
destabilizing mutant suggested that small structural perturba-
tions of the hinge region linking the substrate- and NAD-bind-
ing domains are sufficient to weaken the CtBP1 tetramer. These
results strongly suggest that the tetramer is important in CtBP
function, and the series of CtBP mutants reported here can be
used to investigate the physiological role of the tetramer.
C-terminal binding proteins 1 and 2 (CtBP13 and CtBP2) are
paralogous transcriptional co-regulators thatmodulate numer-
ous cellular processes by binding transcription factors and
recruiting chromatin remodeling enzymes such as histone
deacetylases, methyl transferases, and demethylases to targeted
promoters (1–3). CtBP1 was first identified through interac-
tions with the C-terminal region of the adenovirus E1A onco-
protein and the ability tomodulate E1A-transforming activities
(4, 5). CtBP co-transcriptional function is important in normal
embryogenesis, as it is a regulator of the epithelial-to-mesen-
chymal transition and is integral in proper fetal cell differenti-
ation. Knockout experiments in mice reveal distinct roles for
CtBP1 and CtBP2 in development, with the loss of CtBP2
embryonically lethal, whereas CtBP1-null mice are small but
the majority survive (6). Alternate splice forms of CtBP1 and -2
also have nonnuclear roles, includingmembrane trafficking (7).
Both CtBP paralogues have been implicated as global repres-
sors of the epithelial phenotype and of apoptotic pathways (1),
and numerous lines of evidence implicate human CtBP in can-
cer progression. CtBP is a corepressor of genes including tumor
suppressive pro-apoptotic factors (Bik andNoxa), cytoskeletal/
cell adhesion molecules (keratin-8 and E-cadherin), and cell-
cycle inhibitors (2, 8). CtBP has also been found to act as a
coactivator of growth andmetastasis-related genes (Tiam1 and
MDR1 and certain Wnt target genes), which facilitate the epi-
thelial-to-mesenchymal transition (9–11). Consistent with its
role in repression of apoptotic pathways and activation of
growth and metastasis, CtBP is up-regulated in a number of
cancer tissues, including colorectal cancer (12),melanoma (13),
metastatic prostate cancer (14), esophageal squamous cell car-
cinoma (15), ovarian cancer (16), and breast cancer (17, 18).
Strikingly, elevated levels of CtBP in tumor tissue have been
correlated with poorer survival in breast cancer (19), ovarian
cancer (16), and hepatocellular carcinoma (20). Recent results
add to evidence of a link between CtBP and cancer progression
by showing increased survival of APCmin/ mice when CtBP2
levels are lowered by CtBP2/ heterozygosity (21).
CtBP is unique among transcription factors in the incorpo-
ration of a D-isomer–specific 2-hydroxyacid dehydrogenase
domain, which reduces or oxidizes substrates using the
coenzyme NAD(P)/NAD(P)H (22, 23). The best substrate
identified to date for CtBP is 4-methylthio-2-oxobutyric acid
(also known as MTOB or 2-keto-4-methylthiobutyrate) (24),
although whether this is a physiologically relevant substrate is
unknown. Whereas evidence indicates that catalytic activity is
not required for some CtBP activities (8, 25), mutant studies
suggest that catalytic activity of CtBP can be important forDro-
sophila melanogaster development (26).
This work was supported by National Institutes of Health Grant R01
GM119014 (to W. E. R.). The authors declare that they have no conflicts of
interest with the contents of this article. The content is solely the respon-
sibility of the authors and does not necessarily represent the official views
of the National Institutes of Health.
The atomic coordinates and structure factors (codes 6CDF and 6CDR) have been
deposited in the Protein Data Bank (http://wwpdb.org/).
1 Present address: Dept. of Structural Biology and Dept. of Chemistry, Univer-
sity of Pittsburgh, Pittsburgh, PA 15260.
2 To whom correspondence should be addressed: Dept. of Biochemistry and
Molecular Pharmacology, University of Massachusetts Medical School,
Worcester, MA 01605. E-mail: William.Royer@umassmed.edu.
3 The abbreviations used are: CtBP, C-terminal binding protein; MALS, multi-
angle light scattering; SEC, size-exclusion chromatography; r.m.s., root
mean square; dH2O, distilled H2O.
croARTICLE
J. Biol. Chem. (2018) 293(23) 9101–9112 9101
© 2018 Bellesis et al. Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.
 at U
niversity of M
assachusetts M
edical Center/The Lam
ar Soutter Library on O
ctober 26, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Regulation of gene expression through the oligomerization
of transcriptional factors is an important paradigm (27, 28). In
the case of CtBP, substantial evidence exists that oligomeriza-
tion is linked with NAD(H) binding (3, 25, 29–32), and dimer-
destabilizing mutants have been found to inhibit transcrip-
tional function (33–36). Assembly of CtBP has primarily been
considered in terms of dimers, as NADH-bound CtBP crystal
structures reveal a predominant dimer with extensive interac-
tions between subunit pairs (23, 37, 38). There is, however, evi-
dence for assembly of CtBP into tetramers (29–31) at least
when the full C terminus is present. Here, we present multi-
angle light scattering (MALS) data showing that the predomi-
nant formofCtBP1 andCtBP2whenbound toNAD(H) is tetra-
meric, with tetramers forming even in the absence of the full C
terminus. Moreover, our mutant data provide strong evidence
that the solution tetramer is very similar to the tetrameric
assembly observed within crystals of the minimal dehydroge-
nase domains for both CtBP1 and CtBP2. Furthermore, the
crystal structure of the CtBP1 A123V mutant reported here
suggests that small perturbations in the flexible hinge region are
capable of destabilizing the CtBP tetramer.
Results
MALS shows that both CtBP1 and CtBP2 assemble into
tetramers in the presence of NADH and NAD
We investigated the oligomeric state of CtBP1 and CtBP2
usingMALS linkedwith size-exclusion chromatography (SEC).
Our initial experiments were carried out using the minimal
dehydrogenase domain constructs that we had previously used
for crystallization, CtBP1(28–353) and CtBP2(31–364) (37). In
contrast with a previous report (30), our SEC-MALS experi-
ments on CtBP lacking the full C terminus showed molecular
weights considerably larger than dimers in the presence of suf-
ficient NADH (Fig. 1A). SEC-MALS results for CtBP oligomer-
ization as a function of NADH concentration are shown in Fig.
2A and Table 1. Fitting of the molecular mass dependence on
NADH concentration (see “Experimental procedures”) yields
an EC50 value for the effect of NADH promoting tetramer for-
mation of about 275 nM for CtBP1(28–353) and 180 nM for
CtBP2(33–364) (Table 1). The EC50 value will probably be sim-
ilar to the dissociation constant for NADH binding; however,
the linkage between NADH binding and tetramer assembly
suggests that the dimeric and tetrameric forms of CtBP will
bind NADH with different affinities, precluding accurate esti-
mates of dissociation constants with the present data.
The MALS molecular mass estimates indicate heterogene-
ousmixtures, corresponding primarily to dimers and tetramers
of CtBP, but also monomers in some cases. Given that light
scattering provides weight average molecular mass estimates
(Mw) (39), one can calculate approximate fractions of dimers
and tetramers, assuming those are the only species contributing
to the light scattering (see “Experimental procedures”). Based
on these assumptions, CtBP2(31–364) is18% tetramer in the
absence of NADH and rises to about 47% tetramer in the pres-
ence of 10 M NADH. In contrast, CtBP1(28–353) appears to
be a mixture of monomer and dimer in the absence of NADH
but is about 46% tetramer in the presence of 10MNADH.Our
findings of significant tetramer formation in the absence the
full C terminus contrast with an earlier report (30); this proba-
bly results from the higher protein concentration used in our
experiments. (The loading concentration of 2 M in the Madi-
son et al. experiments (30) is substantially lower than our load-
ing concentrations of 20 M and will become even more
diluted during the50-ml run through the SEC column before
CtBP elution compared with the10-ml run before CtBP elu-
tion in our SEC-MALS experiments.)
Given previous findings suggesting the importance of the
C-terminal residues for tetrameric assembly (30), we investi-
gated constructs that included the full C terminus: CtBP1(28–
440) and CtBP2(31–445) (Fig. 1B). Our results show that both
assemble with masses indicative of predominantly tetramers in
the presence of micromolar levels of NADH (Fig. 2B and Table
2). Assuming a simple mixture of dimers and tetramers,
CtBP2(31–445) in the absence of added NADH is about 29%
tetramer and plateaus to 75% tetramer at micromolar levels of
NADH. CtBP1(28–440) shows only 15% tetramer in the
absence of addedNADH, but this plateaus to 79% tetramerwith
sufficient NADH. Thus, in agreement with Madison et al. (30),
our experiments suggest that significantly stronger tetramers
form in the presence of the full C terminus. Our results also
suggest that the affinity of CtBP1 for NADH is slightly higher in
constructs with the C terminus (EC5050 nM) compared with
those lacking the final85 residues (EC50275 nM); however,
for CtBP2, the differences are smaller (EC50 180 nM versus
110 nM).
We also investigated the effect of NAD on CtBP tetramer
formation (Fig. 2B). For CtBP1(28–440), we observed an EC50
for NAD of 140 nM compared with NADH of 50 nM. For
CtBP2(31–445), the EC50 values are almost identical forNAD
(98 nM) andNADH (107 nM).Notable from the curves in Fig. 2B
are steeper slopes for NADH-dependent tetramer assembly
compared with the slopes for NAD assembly, which is
reflected in the fitted Hill coefficients (Table 2). This suggests
potentially greater cooperativity in NADH-linked assembly of
CtBP,which could be relevant for the response ofCtBP to coen-
zyme binding. Although the fitted EC50 values are indirectmea-
surements of binding affinity, our results are consistent with
similar affinities for NAD andNADH as reported byMadison
et al. (30). Our apparent affinities for NADH are similar to that
reported by Goodman and colleagues (40–42), but our results
are inconsistent with the much lower affinity reported for
NAD (40).
Tetramermodels based on crystal lattices of CtBP1 and CtBP2
Observation of tetramer formation even for the crystallized
minimal dehydrogenase domain suggested that the crystals
grown from high CtBP concentrations might show assemblies
related to the tetramers detected in our SEC-MALS experi-
ments. Examination of the CtBP crystal lattices reveals strik-
ingly similar tetrameric arrangements for both CtBP1 and
CtBP2, despite very different crystal lattices (Fig. 3). CtBP1
crystallizes with one subunit in the asymmetric unit of hexago-
nal space group P6422 (23, 43). Three mutually perpendicular
intersecting crystallographic 2-fold axes generate the D2 sym-
metric tetramer shown in Fig. 3A. The CtBP2 crystal lattice has
Assembly of tetrameric CtBP
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eight subunits per asymmetric unit (37). These eight subunits
are assembled into two tetramers, as shown in Fig. 3 (B and C).
The remarkable similarity of these three tetramers is evident,
which is confirmed by structural alignment of the full tetram-
ers. The two CtBP2 tetramers align with a root mean square
(r.m.s.) deviation of 0.441 Å (for 8083 atom pairs), and the
CtBP1 tetramer aligns to each CtBP2 tetramer with r.m.s. val-
ues of 0.733 Å (for 7925 atom pairs) and 0.711 Å (for 7776 atom
pairs). By far the most extensive interface occurs between two
subunits that form the dimer first identified inCtBP1 byKumar
et al. (23), which buries surface areas of 2715–2924Å2 in CtBP1
and CtBP2. Contacts between two dimers are more limited,
with pairs of subunits burying surface areas of 806–857 Å2
(buried surface area calculated with PDBePISA (44)). Thus,
the tetramer is a dimer of dimers, encompassing an extensive
intradimer interface and a less extensive interdimer interface.
CtBP subunits comprise an NAD-binding domain (residues
125–319 for CtBP1 and 131–325 for CtBP2) and a discontinu-
ous substrate-binding domain (residues 28–120 and 320–353
for CtBP1; 34–126 and 333–359 for CtBP2). These two
domains are connected at residues 320–321 and also by a hinge
region including residues 121–124 (CtBP1) and 127–130
(CtBP2), which contributes to the interdimer contacts.
Evident upon examining the CtBP subunit arrangement is a
short helix in the NAD binding domain (helix E, as defined by
Kumar et al. (23)), whose projection into the solvent in
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Figure 1. SEC trace andMALSmolecularmasses for the previously crystallized CtBP2(31–364) construct (A) and long (residues 31–445) construct (B)
at various levels ofNADH. The continuous lines show the light-scatteringRayleigh ratio (arbitrary units) for protein elution from the SEC column, and the small
diamonds show themolecularmassmeasuredbyMALSmeasurements for the elutionpeaks.A, the additionofNADH to10M results in earlier elution from the
SEC columnandan increase inmolecularmass from106 to 132 kDa (Table 1).B, assembly as a functionofNADHconcentration ismorepronounced for theCtBP
construct including the full C terminus, with molecular masses of 142 kDa in the absence of NADH increasing to 182 kDa at 10 M NADH (Table 2). (Multiple
measurements demonstrate that these results are fully reproducible.)
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dimeric CtBP would appear to be unfavorable. The tetramer
buries this short helix in a pocket between D and E helices
of a partner subunit (Fig. 3), potentially providing a more
favorable environment.
The arrangement of subunits in the crystallographically
observed CtBP tetramers has intriguing features as a potential
model for the observed solution tetramer. Interdimer contacts
are formed from the NAD-binding domain along with the
hinge region between the NAD-binding and substrate-binding
domains. Strikingly, each subunit projects its C terminus
toward the interdimer interface, suggesting that the presence of
an additional 85 C-terminal residues may provide interac-
tions to stabilize the tetrameric form, consistent with our
MALS results and the results of Madison et al. (30). Addition-
ally, bound NAD(H) coenzymes are in closer proximity across
the interdimer interface than across the intradimer interface,
suggesting that the interdimer interface may be sensitive to
100
150
200
   
   
   
   
   
   
   
   
   
   
  M
A
LS
 M
w
  (
kD
a)
   
  
CtBP1(28-440) NADH
CtBP2(31-445) NADH
CtBP1(28-440) NAD+
CtBP2(31-445) NAD+
Dimer
Tetramer
1 10 100 1000 10000
Full C-terminal Constructs
B
[NAD(H)] nM
50
100
150
  M
A
LS
 M
w
 (k
D
a)
CtBP1 (28-353)
CtBP2 (31-364)
Dimer
Tetramer
[NADH] nM
1
Crystallized Constructs
10 100 1000 10000
A
Figure 2. Dependence of MALS-determined CtBP molecular masses as a function of NAD(H) concentration (see Tables 1 and 2). The approximate
molecular masses expected for a pure dimer (left) and tetramer (right) are indicated. The data were fit with Prism version 7 (see “Experimental procedures”). A,
MALS-measured Mw values for the crystallized constructs of CtBP1 and CtBP2 as a function of NADH concentration. In the absence of NADH, the Mw of
CtBP1(28–353) of 62 kDa indicates amixture ofmonomer and dimer, and this value rises to 128 kDa, consistentwith about 46% tetramer, in the presence of 10
MNADH. For CtBP2(31–364), theMwof 106 kDa is consistentwith amixture ofmostly dimer and about 18% tetramer,which rises to about 50% tetramer in the
presence of 10MNADH. B, MALS-determinedMw values for the constructs CtBP1(28–440) and CtBP2(31–445) with the full C terminus as a function of NADH
andNAD. (Theseexperimentswere carriedout in triplicate; error barsare shownbut areoften smaller than thedatapoint shown.) In theabsenceof coenzyme,
CtBP1has anMw, consistentwith about 15% tetramer,whereasCtBP2has anMw, consistentwith about 30% tetramer. These values rise to 61 and66% tetramer
in thepresenceof 10MNAD for CtBP1andCtBP2, respectively, and to79and75%tetramer in thepresenceof 10MNADH forCtBP1andCtBP2, respectively.
Table 1
Molecularmass values as a function of NAD(H) concentration for crys-
tallized constructs
Assembly of tetrameric CtBP
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NAD(H) binding. Finally, an Arg side chain (Fig. 3E) provides a
direct link between an NAD(H) bound in one subunit with a
subunit across the interdimer interface, as discussed below.
Thus, the crystallographically observed tetramer provides a
detailed and plausible model for the solution tetramer.
Mutational investigation of tetramermodel
Based on the tetramer model described above, we designed a
series of site-directedmutants for bothCtBP1 andCtBP2 to test
the hypothesis that the observed interdimer interface stabilizes
the solution tetramer. Three groups of residues were investi-
gated, all of which should primarily impact the interdimer
interface. 1) A nonpolar interaction along the 2-fold axis relat-
ing two dimers involves Leu221 (215 in CtBP1) from the short
E helix (23) of each subunit (Fig. 3D). The atoms from the
leucine side chains come within 3.6 Å of each other in CtBP1
and are 3.8–4.8 Å from each other in the lower-resolution
CtBP2 structure.Wemutated this leucine to the largerTyr. 2)A
particularly intriguing interaction involves Arg190 (Arg184 in
CtBP1) (from the amino end of D (23)), which forms ionic
hydrogen bondswith theNAD(H) phosphate in its own subunit
and themain-chain carbonyl ofAsp215 (Asp209 inCtBP1) across
the interdimer interface (Fig. 3E). To test the need for a charged
Arg that can donate hydrogen bonds to both groups, we
mutated this residue to a Gln. 3) The third group includes res-
idues in the hinge between the NAD and substrate-binding
domains of CtBP (Fig. 3F). The contacts involving the hinge
regions were interrogated with mutations of Ser128 (Ala122 in
CtBP1) to Thr, to test the contact itself and of Ala129 (Ala123 in
CtBP1) to the larger Val and Leu, to test whether bulkier resi-
dues at this position could alter the hinge conformation and
destabilize the interdimer interface. Mutants for both CtBP1
and CtBP2 were constructed in the context of the full C termi-
nus, purified, and subjected to SEC-MALS to investigate the
effect on tetramer formation.
Results of SEC-MALS experiments, run with 10 M NADH,
on the CtBP2 mutants are shown in Fig. 4A and Table 3. The
dimeric molecular mass for the CtBP2(31–445) construct is
98.0 kDa. WT CtBP2 ran as mostly tetrameric in these experi-
ments, with a MALS molecular mass measured to be 185 kDa.
All six putative interdimer-destabilizing mutants eluted at a
similar volume (Fig. 4A), with MALS-determined molecular
masses of 94–103 kDa. Thus, our results are fully consistent
with these mutants destabilizing the tetramer but maintaining
their dimeric assemblages, as predicted from the crystallo-
graphic tetramer model.
The SEC traces for the CtBP1 mutants are more complex
than those for CtBP2 (Fig. 4B). SDS-polyacrylamide gels dem-
onstrate that the C-terminal region of CtBP1 is more suscepti-
ble to proteolytic cleavage than that of CtBP2. An SDS-poly-
acrylamide gel of the samples used in this experiment indicated
that all mutants showed some proteolysis in the C-terminal
region. All mutants except for R184Qdisplayed amajor band at
a full-length size of 47 kDa, whereas the major band for R184Q
was at a molecular mass of about 41 kDa, consistent with a
sequence ending at approximately residue 378. (The CtBP1
crystals discussed below, grown from constructs expressing the
full C terminus, were found to have been proteolyzed just after
residue 378.) The greater C-terminal proteolysis for CtBP1,
compared with CtBP2, suggests that the C terminus may be
more flexible in CtBP1. Such increased flexibility, along with
partial proteolysis, may contribute to the observed greater var-
iation in elution volumes for CtBP1mutants, as the SEC elution
depends upon overall protein shape rather than strictly on the
molecular mass. (The C-terminal 86 amino acids are the least
conserved, with only a 51% sequence identity between human
CtBP1 and CtBP2, compared with 89% identity in the crystal-
lized minimal dehydrogenase domain.) The MALS molecular
mass values show smaller variations, providing more accurate
estimates of the oligomeric state. The four CtBP1 mutants of
residues projecting into the interdimer interface show MALS
molecular masses of 84–100 kDa (Table 3). These are in the
range expected for dimers of CtBP1(28–440) of 94 kDa and
those for partially proteolyzed species (residues 28–378) of 82
kDa. These results, thus, support those from CtBP2 indicating
that the interdimer interface is similar to that observed in the
crystallographic tetramer.
Themost subtlemutants designed to destabilize the tetramer
were of Ala123/129 (CtBP1/CtBP2), residues that are in the hinge
region but project their -carbon into its subunit rather than
toward the interdimeric interface. In this case, the results
between CtBP1 and CtBP2 show some interesting differences.
Whereas CtBP2 A129V and A129L were found to have molec-
ular masses close to that expected for dimers, the equivalent
Table 2
Molecular mass values as a function of NAD(H) concentration for full
C-terminal constructs (experiments carried out in triplicate)
Assembly of tetrameric CtBP
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CtBP1 A123V and A123L showmolecular masses between that
of dimers and tetramers, suggesting a more subtle destabiliza-
tion of the CtBP1 interdimer interface (Table 3). These results
indicate that subtle conformational changes in the hinge region
connecting the two domains can substantially impact tetramer
stability.
Crystal structures of CtBP1with extended C terminus
Our results, complementing those of Madison et al. (30),
highlight the contribution of the final 85 residues to stabili-
zation of the CtBP tetramer. In an attempt to investigate
the C-terminal residues and also the conformational changes
induced by mutation of hinge residues, we grew crystals from
CtBP1 expressed with the full C terminus for WT and a subtle
tetramer-destabilizingmutant (A123V), both in the presence of
NADH. (Attempts to grow crystals of A123L, with its slightly
larger side chain, were unsuccessful.)
Crystallization of expressed CtBP1(28–440) was successful
only intermittently; SDS-polyacrylamide gels revealed that
those samples that successfully crystallized were intermediate in
size between CtBP1(28–440) and CtBP1(28–353). Mass spec-
trometry measurements confirmed that these samples were
shorter than full-length, with a predominant species encom-
passing residues 28–378. We therefore consider these crystal
structures to be CtBP1(28–378).
All CtBP crystals described to date are built from tetrameric
assemblies, although they have not previously beendescribed as
such. Thus, it is not surprising that only a subtle tetramer-de-
stabilizing mutant (A123V) successfully crystallized. The crys-
tal structures of bothWTandA123Vmutantswere determined
by molecular replacement using the CtBP1-HIPP structure
(residues 28–353) (43) and refined to resolutions of 2.6 and
2.4 Å, respectively. (The resolution cutoffs were conserva-
tively chosen.) Final crystallographic statistics are provided
in Table 4.
Despite an additional 25 residues in the WT and A123V
CtBP1(28–378), only four additional residues are evident in the
electron density maps and modeled in our final structures (Fig.
5). These results are consistent with findings on rat CtBP that
the C terminus is largely disordered (31).
The isomorphous crystal lattices for WT and A123V
CtBP1(28–378) permit direct comparison of the structural dif-
ferences using difference maps (Fo(A123V)  Fo(WT)). As is
evident from Fig. 6, the mutation-induced changes largely
localize to the mutant site. Substitution of Val for Ala at posi-
tion 123 induces movements of Glu326 and the 5 helix (23)
(which includes Glu326) deeper into the subunit. Interestingly,
themaps donot suggest significantmovement of residues in the
partner subunit across the tetrameric interface. This observa-
tion suggests that the tetrameric subunit arrangement is suffi-
ciently stabilized by the CtBP1 crystal lattice that any strain
induced by Val123 is absorbed within a subunit. Our MALS
results, however, clearly show that the tetramer is destabilized
CtBP1 Tetramer
R190
G216’
D215’
L221
L221’
2# remarteT 2PBtC1# remarteT 2PBtC
S128
A129
A CB
FED
C-term
C-termC-termC-termC-termC-term
αE
NADH
αE
αE
Figure 3. Crystallographic structures of tetramers for CtBP1 (43) and CtBP2 (37). A, arrangement of four subunits of CtBP1 (PDB code 4U6Q), related by
crystallographic symmetry in the spacegroupP6422, forminga tetramer. Themain-chain trace is shown inmagenta for two subunits and cyan for two subunits,
except for the C-terminal residues, which are displayed in orange. A stickmodel of the NAD(H) is shownwith yellow carbon atoms. B and C, two crystallographi-
cally independent tetramers in the asymmetric unit of CtBP2 (PDB code 4LCJ). Note the remarkably similar arrangement of subunits in these three crystallo-
graphically independent tetramers, each subunit of which projects its C terminus toward a partner subunit across the interdimer interface. D–F, enlarged
regions of the interdimer contact for CtBP2 tetramer 1. Each of these regions was investigated by site-directed mutagenesis (Fig. 4).
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by the mutation, such that in solution there may be significant
effects on the interaction between the partner subunits with
this mutation. The observation that the homologous mutation
(A129V) in CtBP2 is almost entirely dimeric suggests that the
CtBP2 subunit structure is unable to accommodate the strain
induced by the presence of the Val129.
Discussion
Assembly of protein components is an important theme in
transcriptional regulation (45–47). A central element of this
process is often the oligomerization of one or more individual
protein components contributing to transcriptional complex
assembly (27, 28). In the case of CtBP, strong evidence exists for
the role of NAD(H) in both co-transcriptional activity and olig-
omerization (3, 23, 25, 29, 32, 33). Previously published results
have provided evidence that CtBP can assemble to dimers and
larger species (3, 25, 29–32) but have not provided a quantita-
tive relationship for the NAD(H) dependence of tetramer
assembly nor a stereochemical model of the CtBP tetramer.
The results presented here demonstrate a clear relationship
betweenNAD(H) binding (with an affinity in the 100 nM range)
and CtBP assembly into tetramers. Our mutant data provide
strong evidence that subunits in the solution tetramer are
arranged similarly to the tetrameric assemblages present in pre-
viously determined crystal structures of human CtBP1 and
CtBP2 (23, 37) and ratCtBP/BARS (38). This tetramer is assem-
CtBP2 (31-445)
Wild-type (185kDa)
A129V (105kDa)
L221Y (102kDa)
S128T (99kDa)
A129L (100kDa)
G216N (94kDa)
R190Q (94kDa)
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Wild-type
(181kDa)
  A123L
(132kDa)
  A123V
(125kDa)
  A122T 
(100kDa)
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Figure 4. SEC trace and MALS molecular masses for mutants of CtBP2(31–445) (A) and CtBP1(28–440) (B) in the presence of 10 M NADH (see also
Table 3). The continuous lines show the light scattering Rayleigh ratio (arbitrary units) for protein elution from the SEC column, and the small diamonds show
themolecularmassmeasured byMALSmeasurements for the elution peaks. TheMALS-determinedMw is shown in parentheses forWT and eachmutant.A, the
six CtBP2 mutants show similar elution volumes and molecular masses that range from 94 to 103 kDa, consistent with primarily dimeric species. B, the
equivalent six CtBP1mutants show a greater range of elution volumes thatmay result from partial proteolysis within the C-terminal region. Molecular masses
for the four mutants whose WT side chains point directly into the interdimer interface, ranging from 84 to 100 kDa, are also consistent with primarily dimeric
species. The two hinge region mutants that point into the subunit, A123V and A123L, have molecular masses of 126–132 kDa, suggesting some tetrameric
species (20–25%), but with the majority of molecules as dimeric. (MALS measurements on all mutants have been carried out multiple times and are fully
reproducible.)
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bled from the pairing of two dimers to form NAD(H)-sensitive
interdimer contacts primarily using the NAD-binding domain
of CtBP. In this tetramer, the closest approach of NADH mol-
ecules across the intradimer interface is over 30 Å but less than
15 Å across the interdimer interface (see Fig. 3); this closer
approach supports the idea that the interdimer interface would
be more sensitive to NADH binding than the intradimer inter-
face. Moreover, the interaction between NADH across the
interdimer interface to themain-chain carbonyl of residue 209/
215 (CtBP1/CtBP2) mediated by Arg184/190 (Fig. 3E) provides
an ionically mediated contact across the interdimer interface
that should be directly sensitive to NAD(H) binding.
Although NAD(H) stabilizes the CtBP tetramer, some
tetramer formation is evident even in the absence of NAD(H)
from our experiments. The ability to form tetramers in the
absence of NAD(H) allowed Nardini et al. (48) to grow crystals
and determine the structure of the NAD(H) binding–impaired
G172E mutant rat CtBP1/BARS protein by using seeding with
NADH-bound CtBP crystals. These crystals, which are isomor-
phous to the human CtBP1 crystals described above, have a
tetramer as their fundamental unit despite no bound coen-
zyme. This result shows the ability of NAD(H)-free CtBP to
form tetramers, which can be stabilized by lattice interactions
triggered by the crystal seeding. The strength of lattice interac-
tions to stabilize the tetramer is also evident in our A123V crys-
tal structure, which, despite having a tetramer-destabilizing
mutant, maintains tetramer contacts, by absorbing mutant-in-
duced strain within a subunit.
Previous investigations into the role of assembly in CtBP
have investigated the activity of mutants specifically designed
to disrupt the CtBP dimer (33–36). Our results strongly suggest
that the CtBP dimer is required for the assembly of a CtBP
tetramer formed from the pairing of two CtBP dimers. There-
fore, it is likely that dimer-destabilizingmutants will also desta-
bilize CtBP tetramers. Thus, previous work showing the impor-
tance of dimers is fully consistent with an important role for
tetramers.
Our results suggest that the tetramer, assembled as observed
in crystal lattices,may be important forCtBP co-transcriptional
activity. Importantly, there is an observed correlation between
elevated levels ofCtBP andpoor prognosis in breast cancer (19),
ovarian cancer (16), and hepatocellular carcinoma (20) as well
as the observation of elevated CtBP levels in other cancers (12–
15). Increased levels of CtBP will not only raise the concentra-
tion of co-transcriptional factor but also increase the propor-
tion of CtBP that assembles into tetramers, thus potentially
increasing its transcriptional activity. Tetramer-destabilizing
mutants identified here provide important tools for dissecting
the role of CtBP tetramers in co-transcriptional function and
cancer progression. Moreover, our model of the tetrameric
assembly provides stereochemical details, for the first time, that
can be used with structure-based drug design approaches for
development of novel CtBP tetrameric destabilizing inhibitors.
Experimental procedures
Expression andmutagenesis of CtBP1 and CtBP2
The expression and purification procedures were adapted
and optimized from earlier studies (37, 43). The ligated, puri-
fied plasmid containing the desired CtBP construct was trans-
formed into Z-competent BL21(DE3)RIL Escherichia coli cells.
A single clonal colony was then grown in a starter culture of
lysogeny broth overnight at 37 °C. The starter culture was used
to inoculate between three and six 1-liter cultures grown in
Research Products International Terrific Broth using 50 ml of
starter/liter. Cultures were grown at 37 °C while shaking at 150
rpm and inducedwith isopropyl 1-thio--D-galactopyranoside,
at a final concentration of 0.2 mM, after reaching A600 between
0.800 and 1.00. The temperature was reduced to 30 °C at the
time of induction, and the cells were harvested 4 h later. The
cells were pelleted by centrifuging for 20 min at 4700 rpm and
resuspended in 10 ml of harvesting buffer (pH 7.6; 0.1 M NaCl,
0.05 M Tris-HCl, 0.2 mM EDTA) per liter of culture. One tablet
of EDTA-free complete Mini (Roche Diagnostics) protease
inhibitor mixture was added per liter of culture, and the cells
were frozen at 80 °C. Site-directed mutants were created
using theQuikChange protocol (Stratagene) using themodified
approach of Liu and Naismith (49).
Purification of CtBP1 and CtBP2
Cells were thawed slowly on ice and then lysed in aMicroflu-
idics Corp. model 1109 cell disrupter. 35mg of Roche Diagnos-
tics DNase I, 500 l of 2 M MgCl2, and 500 l of 40 mM CaCl2
were added per 100 ml of lysate. The lysate was then gently
stirred at 4 °C for 30 min before the insoluble fraction was pel-
leted by centrifuging at 19,000 rpm for 45min. The supernatant
was then mixed with 8 ml of HisPurTM nickel-nitrilotriacetic
acid resin (Thermo Scientific) and gently stirred at 4 °C for 2 h
to allow CtBP to bind to the resin.
The bead/supernatant mixture was placed in a Bio-Rad
Econo-Column at 4 °C, and the soluble fractionwas allowed to
flow through. The beads were then cleaned with 5 column vol-
umes of wash buffer (0.0625 M Tris-HCl, pH 7.4, 0.375 M NaCl,
0.05 M imidazole, 0.625mM EDTA, 1.0mMDTT), followed by 6
column volumes of wash buffer supplemented with an addi-
tional 1.7 M NaCl. Another 2 column volumes of wash buffer
was passed over the beads before 6 column volumes of wash
buffer supplemented with 0.5% Triton X-100 was added. An
additional 2 column volumes of wash buffer again followed.
CtBP was eluted from the beads using 3 column volumes of
Table 3
Molecular mass values for CtBPmutants
Mutant/WT form M w
Elution peak
concentration Tetramer
kDa M %
CtBP2(31–445)
WT 185 2.8 80
A129L 100 3.3 4
A129V 105 3.5 1
L221Y 102 3.5 2
S128T 99 3.4 0.5
G216N 94 2.9 0
R190Q 94 2.0 0
CtBP1(28–440)
WT 181 2.3 86
A123L 132 3.3 25
A123V 125 2.3 20
L215Y 90 1.8 0
A122T 100 3.6 3
G210N 86.8 1.4 0
R184Q 83.6 2.2 0
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wash buffer supplemented with 250 mM imidazole. The eluent
was collected and dialyzed overnight in SnakeSkin dialysis
tubing (Thermo Scientific) to remove imidazole. The dialysis
buffer consisted of 50mMTris-HCl, pH7.7, 300mMNaCl, 5mM
EDTA, 2 mM DTT, and 10% glycerol. The protein was then
concentrated by centrifuging at 5000 rpm in an Amicon
Ultra-15 10K centrifugation column (Millipore). Protein con-
centration wasmeasured by UV absorbance at 280 nm using an
Ultraspec 2100 pro by Amersham Biosciences.
The protein sample was further purified by size-exclusion
chromatography. The FPLC (A¨TKAprime plus by GE Health-
care) and size-exclusion column (HighloadTM 16/60 SuperdexTM
200 preparation grade) were equilibrated with “FPLC buffer”
(50 mM Tris-HCl, pH 7.7, 300 mM NaCl, 5 mM EDTA, 2 mM
DTT). The sample was prepared by adding 1.5 mM NADH to
the concentrated protein solution; the solution was then cen-
trifuged at 8000 rpm for 6 min at 4 °C to remove any small
insoluble fraction. The flow rate was set to 1 ml/min, 62 frac-
tions of 2 ml each were collected, and the appropriate fractions
were concentrated in an AmiconUltra-15 10K centrifugation
column.
SEC-MALS for NAD(H)-dependent oligomerization studies
Four different CtBP constructs were tested in NAD(H)-de-
pendent oligomerization MALS experiments: CtBP1(28–353),
CtBP1(28–440), CtBP2(31–364), and CtBP2(31–445) were
expressed and purified as described above. Protein samples
were prepared for SEC-MALS by diluting CtBP stocks to 1.0
mg/ml in FPLC buffer supplemented by the desired concentra-
tion of NAD(H). The protein samples were filtered through a
Costar 0.22-m Spin-X column at room temperature. 100-l
protein samples were injected into the SEC-MALS instrument.
The MALS system consisted of a Dawn Helios-II MALS detec-
tor (Wyatt), an Optilab T-rEX differential refractive index
detector (Wyatt), and the 1260 Infinity HPLC system (Agilent)
with a Wyatt Corp. 0.78  30-cm HPLC column with 500-Å
pore size. In later experiments, a TSKgel G3000SWxl column
(Tosoh Bioscience) was substituted, but the effect of the col-
umn on the quality of the data obtained was negligible. For the
WTconstructswith the full C terminus,measurements at given
NADHandNAD concentrationswere carried out in triplicate
(Table 2 and Fig. 2B).
The data for the dependence onmolecularmass as a function
of NAD(H) concentration (Fig. 2) were fit with Prism version 7
(GraphPad Software, Inc.) to the equation, Y  L  (U  L)/
(1  10log(EC50 x)n), where L and U are the lower and upper
Mw plateaus, respectively, x is the concentration of NAD(H) in
nM, and n is the Hill coefficient.
The molecular mass obtained from light scattering from a
heterogeneous mixture of protein molecules is theMw:Mw 
NiM2i/NiMi, where Ni is the molar or fractional concentra-
tion (39). Assuming a mixture of just CtBP dimers and tetram-
ers allows simplification toMw (FT(2MD)2 (1 FT)iMD2)/
(FT(2MD)  (1  FT)MD), whereMD is the dimeric molecular
weight and FT is the fraction of CtBP in the tetrameric form.
Rearranging this equation, we obtained estimates of the frac-
tion tetramer from FT (MwMD)/(3MDMw).
SEC-MALS formutant studies
Themutant SEC studies were carried out as described above
using a TSKgel G3000SWxl column (Tosoh Bioscience) work-
ing in concert. The instruments were equilibrated in FPLC
Table 4
Crystallographic data collection and refinement statistics
CtBP1(28–378) WT CtBP1(28–378) A123V
PDB code 6CDF 6CDR
Data collection
Space group P6422 P6422
Unit cell parameters
a, b, c (Å) 88.66, 88.6, 163.91 89.22, 89.22, 164.23
, ,  (degrees) 90, 90, 120 90, 90, 120
Bragg spacings (Å)a 50. to 2.6 (2.693–2.6) 50. to 2.4 (2.485–2.4)
Rmerge 0.0453 (0.2695) 0.0655 (0.4668)
I/I 30.5 (6.3) 27.9 (5.3)
Completeness (%) 95.8 (88.7) 93.3 (99.8)
Redundancy 7.8 (6.8) 12.8 (10.4)
Total reflections 93,207 (7207) 193,860 (15932)
Unique reflections 11,944 (1056) 15,090 (1537)
Refinement
Rwork/Rfree 0.209/0.243 0.235/0.258
No. of non-hydrogen atoms
Protein 2578 2580
Ligands 48 65
Solvent 115 101
Mean B-factors (Å2)
Protein 46.4 44.2
Ligands 36.4 38.1
Solvent 40.3 42.1
r.m.s. deviations
Bond lengths (Å) 0.003 0.003
Bond angles (degrees) 0.67 0.61
Ramachandran (%)
Favored 95.2 95.8
Allowed 4.8 4.2
Outliers 0 0
aHighest-resolution shell shown in parenthesis.
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buffer supplemented with 10 M NADH. Protein samples con-
sisted of 1mg/ml CtBP in FPLC buffer. The sample was filtered
using 0.22 M cellulose acetate Costar Spin-X centrifuge tube
filters at 8000 rpm for 1 min at room temperature. 100 l of
sample solutionwas injected into theMALS system, with a flow
rate of 1.0 ml/min. Data were analyzed using the ASTRA soft-
ware package by Wyatt.
Crystallization and X-ray diffraction
Purified CtBP1(28–378) WT protein was diluted to 18.0
mg/ml from 27.0 mg/ml stock with dH2O before being supple-
mentedwith 10%15mMNADHand 2%100mM tris(2-carboxy-
ethyl)phosphine in dH2O. The sample was then filtered via a
Costar 0.22-mSpin-X column at room temperature. Hanging
vapor diffusion drops were set up in a 1:1 ratio of protein to
mother liquor with a total volume of 4 l and incubated at
20 °C. Crystals formed within 24 h after the drops were set up
but allowed to grow for several days. A single crystal with hex-
agonal bipyramidal morphology was observed in 100 mM
HEPES buffer, pH 7.5, containing 140 mM CaCl2 and 5% PEG
400. The observable dimensions along its longest axes were
260 400 m. The crystal was harvested for data collection by
dipping in a cryoprotectant solution consisting of mother liq-
uor supplemented with 20% ethylene glycol. The crystal was
then flash-frozen at 100K. Data were collected on aMicroMax-
007-HF/Saturn 944CCDX-ray diffraction system (Rigaku) and
then processed with HKL-3000R. The structure was solved
by molecular replacement, using the CtBP1(28–353) HIPP
structure (PDB code 4U6Q (43)) as the search molecule and
refined in PHENIX version 1.11.1-2575-000. Model building
between rounds of refinement was completed with Coot ver-
sion 0.8.8.EL. Data were refined to a maximum resolution of
2.60 Å.
For theCtBP1 28–378A123Vmutant, proteinwas diluted to
17.9 mg/ml from a 33.5 mg/ml stock with dH2O before being
A
B
C-termC-term
D354
H355
T357
L357
Figure 5. Crystal structure of CtBP1(28–378). A, trace of the CtBP1
tetramer, with two subunits inmagenta and two in cyan. Shown with orange
carbon atoms is a stick rendition of the additional four residues observed
compared with the previous CtBP1(28–353) structures. B, Fo Fc difference
electron density map shown in cyan at a 2 level for the four additional
residues (Asp354–Thr357) observed.
A
B
A/V 123A/V 123
 221A 221A
623E623E
Tet 
partner 
subunit
Tet 
partner 
subunit
Figure 6. Crystal structure of CtBP1(28–378) A123V compared with the
structure of WT CtBP1(28–378). A, trace of the CtBP1 tetramer with the
Fo(A123V) Fo(WT)map contoured at4 (blue) and4 (red). The electron
density is localized to themutant region (black rectangles) with the exception
of a negative density peak (red) near the center, which appears to be an
unidentified solvent molecule apparently present in the WT but not in the
A123V structure. B, stereoview of the Fo(A123V)  Fo(WT) electron density
(blue,4; red,4) in the region of themutation. Note the positive density
for the twomethyl carbonatomsof themutantVal,which inducesmovement
of Glu326 toward the left and upward, takingwith it themain chain of helix5,
to which it is attached. There is no evidence of significant movement in the
partner subunit, despite theMALS data showing aweakening of the tetramer
with the A123V mutation.
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supplemented with 10% 15 mM NADH and 2% tris(2-carboxy-
ethyl)phosphine in dH2O. The protein sample was filtered via a
Costar 0.22-mSpin-X column at room temperature. Hanging
vapor diffusion drops were set up in a 1:1 ratio of protein to
mother liquor with a total volume of 4 l and incubated at
15 °C. Crystals formed between 3 and 8 days after the drops
were set up. A single crystal with hexagonal bipyramidal mor-
phology was observed in 100 mM HEPES, pH 7.5, buffer con-
taining 80 mMMgCl2 and 4% PEG 400. The observable dimen-
sions along its longest axes were 160 300m.The crystal was
harvested for data collection after 3.5l of cryoprotectant solu-
tion consisting of mother liquor supplemented with 20% ethyl-
ene glycol was added to the hanging drop and left to soak for 5
min. The crystal was then flash-frozen at 100 K. Data were
collected, solved, and refined as described above. Data were
refined to a maximum resolution of 2.40 Å.
LC/MS
LC/MS samples were prepared by diluting CtBP1 28–440
WT stock andCtBP1 28–440A123V stock to 2.5mg/ml in 16.7
mM Tris-HCl, pH 7.7, buffer supplemented with 100 mM NaCl
and 1.67 mM EDTA. Each sample was spin-filtered in a Costar
0.22-m Spin-X column at room temperature. LC/MS experi-
ments were carried out by Dr. John Leszyk and Dr. Khaja
Muneeruddin of the Proteomics and Mass Spectrometry core
at University of Massachusetts Medical School (Worcester,
MA).
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